Acetyl-Histone H3 (K18) Antibody

What is Histone H3K18 acetylation and its biological significance?

Histone H3 lysine 18 acetylation (H3K18ac) is a post-translational modification occurring on the N-terminal tail of histone H3. It plays a crucial role in chromatin remodeling and regulation of gene expression. H3K18ac is one of the primary acetylated sites of histone H3, alongside K9 and K14, that contributes to the epigenetic regulation of gene expression. This modification is tightly involved in cell cycle regulation, cell proliferation, and apoptosis, and is strongly correlated with transcriptional activation. H3K18 acetylation is mediated by histone acetyltransferases (HATs), particularly CBP/p300, while deacetylation is performed by histone deacetylases (HDACs) .

How does H3K18 acetylation participate in nucleosome structure and function?

Histone H3, featuring a main globular domain and a long N-terminal tail, is a core component of nucleosomes, the fundamental units of chromatin structure often described as "beads on a string" . H3K18 acetylation affects nucleosome stability by reducing the positive charge of the histone tail, weakening histone-DNA interactions. Research published in eLife demonstrates that H3K18ac regulates nucleosome stability and facilitates nucleosome eviction, thereby promoting gene expression in vivo . This modification alters chromatin structure, making DNA more accessible to transcription factors and other regulatory proteins.

What is the relationship between H3K18 acetylation and cancer development?

An imbalance in the equilibrium of histone H3 acetylation, including K18 acetylation, has been strongly associated with tumorigenesis and cancer progression . Recent studies have revealed a correlation between tumor formation and acetylation levels of lysine K18 on histone H3 . Changes in H3K18 acetylation patterns may serve as epigenetic biomarkers for certain cancers. Understanding these patterns has implications for developing both diagnostic tools and therapeutic interventions targeting epigenetic mechanisms in cancer.

What are the key differences between polyclonal and monoclonal anti-H3K18ac antibodies?

Polyclonal antibodies (e.g., from Sigma-Aldrich, Abcam):

• Recognize multiple epitopes on the H3K18ac target

• Often provide higher sensitivity with broader detection capability

• May exhibit batch-to-batch variability

• Example: Rabbit polyclonal H3K18ac antibody (ab1191) suitable for ChIP, Western Blotting, and Immunohistochemistry

Monoclonal antibodies (e.g., Cell Signaling's D8Z5H, RevMab's RM166):

• Recognize a single epitope on the H3K18ac target

• Provide superior specificity and consistency between lots

• Example: RM166 specifically reacts to H3K18ac with no cross-reactivity to other acetylated lysines in histone H3

• Example: D8Z5H (Cell Signaling #13998) is a recombinant rabbit monoclonal with high specificity

Selection should be based on the experimental application, required specificity, and research context.

How do I assess the specificity of H3K18ac antibodies?

Assessment of antibody specificity should involve multiple validation techniques:

• Dot blot analysis: Test against various histone peptides with different modifications

  • Example: Cell Signaling's validation shows strong signal with H3K18ac peptides without cross-reactivity

• Western blot with controls:

  • Positive control: Acid extracts from cells treated with HDAC inhibitors (e.g., sodium butyrate)

  • Negative control: Untreated cell extracts or extracts with other histone modifications

• Peptide competition assays: Pre-incubation with specific and non-specific acetylated peptides

• Use of genetically modified systems: CRISPR/Cas9-mediated mutation of K18 to non-acetylatable residues

A highly specific antibody should demonstrate clear differential binding between acetylated K18 and other acetylated lysines (K4, K9, K14, K23, K27, K36, etc.) on histone H3 .

What species reactivity should I consider when selecting an H3K18ac antibody?

H3K18ac antibodies vary in their species reactivity profiles:

When selecting an antibody, consider the evolutionary conservation of the H3K18 region across your species of interest. The high conservation of histone H3 sequences makes many antibodies suitable for cross-species applications, but validation in your specific model organism is always recommended .

How should I optimize ChIP protocols when using H3K18ac antibodies?

Chromatin Immunoprecipitation (ChIP) with H3K18ac antibodies requires careful optimization:

• Antibody amount: For optimal ChIP results with Cell Signaling's D8Z5H antibody (#13998), use 10 μl of antibody and 10 μg of chromatin (approximately 4 × 10^6 cells) per IP . For the Sigma antibody, the recommended amount is 20 μl with the same amount of chromatin .

• Crosslinking conditions: Standard 1% formaldehyde for 10 minutes at room temperature is typically sufficient for H3K18ac ChIP.

• Sonication parameters: Optimize to achieve chromatin fragments of 200-500 bp.

• Controls:

  • Include IgG negative control

  • Use non-acetylated histone H3 antibody as reference

  • Consider using cells treated with HDAC inhibitors (e.g., sodium butyrate) as positive control

• Validation: Confirm enrichment at known H3K18ac-associated promoters versus gene deserts using qPCR before proceeding to genome-wide analyses.

Real-world example: ChIP performed on HeLa cells with or without sodium butyrate treatment using H3K18Ac antibody (RM166, 5 μg) followed by real-time PCR with gene-specific primers demonstrares enrichment of acetylation at specific genomic regions .

What are the recommended protocols for detecting H3K18ac in Western blotting?

For optimal Western blot detection of H3K18ac:

• Sample preparation:

  • Extract histones using acid extraction (0.2N HCl overnight at 4°C)

  • For enhanced detection, treat cells with HDAC inhibitors (e.g., sodium butyrate) for 2-6 hours prior to extraction

• Electrophoresis conditions:

  • Use 15% SDS-PAGE gels for optimal histone separation

  • Load 5-15 μg of acid-extracted histones per lane

• Antibody dilutions:

  • Primary antibodies: 1:1000 to 1:2000 (Cell Signaling #13998) , 1:2000 (Sigma 07-354)

  • Secondary antibodies: Anti-rabbit IgG conjugated to HRP (typically 1:5000)

• Visualization:

  • Use chemiluminescence detection systems with appropriate exposure times

  • H3K18ac should appear as a single band at approximately 17 kDa

• Controls:

  • Positive control: HeLa acid extracts treated with sodium butyrate

  • Negative control: Untreated cell extracts

When analyzing results, compare the ratio of H3K18ac signal to total H3 to normalize for loading differences .

How can I quantitatively measure H3K18 acetylation levels across different samples?

Several methods allow quantitative measurement of H3K18 acetylation:

• Fluorometric assay kits:

  • Acetyl Histone H3-K18 Quantification Kit (Fluorometric) measures acetylation using fluorescence detection

  • Applicable for various mammalian cells including fresh and frozen tissues, cultured adherent and suspension cells

• Colorimetric assays using gold nanoparticles (AuNPs):

  • Two colorimetric in vitro assays:

    • Assay I: Citrate ion-capped AuNP without modification, mixing K18 peptide with AuNP solution leads to distinct particle aggregation

    • Assay II: AuNP-peptide-antibody composite used as both sensing probe and transducing element

  • Both assays can identify acetylated peptides and differentiate acetylation positions that differ by just three amino acids

• Mass spectrometry-based approaches:

  • Histone H3 proteoform data analysis (as demonstrated with HEK293 cells ± HDAC inhibition)

  • This method provides precise measurement of acetylation stoichiometry at specific lysine residues

• Western blot with standard curves:

  • Create standard curves using recombinant histones with known acetylation levels

  • Use image analysis software to quantify band intensity

  • Normalize H3K18ac signal to total H3 signal

Each method offers different advantages in terms of sensitivity, specificity, and throughput.

How does H3K18 acetylation interact with other histone modifications in the histone code?

H3K18 acetylation functions within a complex network of histone modifications:

• Sequential modifications: In estrogen-responsive genes, histone H3K18 is acetylated by CBP/p300 following estrogen stimulation, leading to acetylation of histone H3K23, and methylation of Arg17 by CARM1. This sequence of modifications leads to transcriptional activation .

• Relationship with H3K4 methylation: Recent research reveals that specific H3 acetylation patterns, including H3K18ac, direct the establishment of MLL-mediated H3K4 methylation. This indicates a histone acetylation-dependent methylation pathway .

• Co-occurrence patterns: H3K18ac often co-occurs with other active chromatin marks such as H3K9ac and H3K27ac, creating combinatorial patterns that define specific chromatin states.

• Modification crosstalk: The presence of H3K18ac can influence the deposition or removal of other histone marks, creating complex regulatory relationships that govern chromatin structure and gene activity.

Understanding these interactions is essential for deciphering the histone code and its role in gene regulation.

How can I differentiate between H3K18ac and other acetylation sites on histone H3 in experimental setups?

Differentiating between various acetylation sites requires careful experimental design:

• Use of site-specific antibodies:

  • Employ highly specific antibodies like RM166 that show no cross-reactivity with other acetylated lysines in histone H3

  • Validate specificity using peptide dot blots with different acetylated histone peptides

• Mass spectrometry approaches:

  • Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can differentiate peptides with acetylation at different positions

  • Specific signature fragment ions can distinguish between different acetylation sites

• Competitive binding assays:

  • Use gold nanoparticle-based assays that can differentiate acetylation positions that differ by just three amino acids

  • These assays demonstrate different aggregation behaviors between K18 acetylated peptides and control sequences

• Genetic approaches:

  • Site-directed mutagenesis of specific lysine residues (K→R mutations) to eliminate specific acetylation sites

  • CRISPR/Cas9-mediated creation of cell lines with non-acetylatable K18 versus other lysine residues

By combining these approaches, researchers can confidently distinguish H3K18ac from other histone H3 acetylation marks.

What methodologies are available for studying the dynamic regulation of H3K18 acetylation during cellular processes?

Several approaches exist for studying dynamic H3K18ac regulation:

• Time-course experiments with ChIP-seq/ChIP-qPCR:

  • Perform ChIP at multiple time points during processes like cell differentiation, cell cycle progression, or response to stimuli

  • Map genome-wide changes in H3K18ac distribution

  • Use cell synchronization methods for cell cycle studies

• Live-cell imaging approaches:

  • Develop and utilize acetylation-specific intrabodies for real-time monitoring

  • FRET-based reporters for specific histone modifications

• Inhibitor studies:

  • HDAC inhibitors (e.g., sodium butyrate) to increase acetylation levels

  • HAT inhibitors to decrease acetylation

  • Time-dependent treatment and washout experiments

• Enzyme activity assays:

  • In vitro assays measuring the activity of HATs (particularly CBP/p300) and HDACs on H3K18

  • Coupled enzyme assays that monitor acetylation/deacetylation rates

• Pulse-chase experiments with isotopically labeled acetyl-CoA:

  • Measure turnover rates of acetyl groups at specific lysine residues

These methods provide valuable insights into how H3K18 acetylation is dynamically regulated in response to various cellular stimuli and developmental processes.

What are the common challenges in H3K18ac antibody-based experiments and how can they be addressed?

Researchers commonly encounter several challenges when working with H3K18ac antibodies:

• High background in immunostaining/Western blotting:

  • Solution: Optimize blocking conditions (try 5% BSA instead of milk)

  • Increase washing steps and duration

  • Titrate antibody concentration to find optimal signal-to-noise ratio

  • Preabsorb antibody with non-specific proteins

• Poor ChIP efficiency:

  • Solution: Optimize chromatin fragmentation (aim for 200-500 bp fragments)

  • Increase crosslinking time for stronger protein-DNA interactions

  • Use fresh antibodies and optimize antibody amounts

  • Include HDAC inhibitors in cell lysis buffers to prevent deacetylation

• Inconsistent results between experiments:

  • Solution: Standardize cell culture conditions and histone extraction protocols

  • Use internal controls for normalization

  • Consider lot-to-lot variations in antibodies (especially polyclonals)

  • Maintain consistent timing in experiments involving dynamic modifications

• Non-specific binding in pulldown experiments:

  • Solution: Increase stringency of wash buffers

  • Pre-clear lysates with protein A/G beads

  • Include competitors like BSA or non-specific IgG

  • Validate results with multiple antibodies from different sources

• Low signal in fixed tissue samples:

  • Solution: Optimize antigen retrieval methods

  • Test different fixation protocols

  • Use amplification systems for signal enhancement

  • Consider fresh frozen samples instead of paraffin-embedded tissues

Addressing these challenges requires systematic optimization and careful controls.

How should researchers interpret conflicting H3K18ac data from different antibodies or experimental approaches?

When facing conflicting data on H3K18ac from different sources:

When publishing, transparently report these considerations and potential limitations of each approach used.

What are the critical factors for successful immunoprecipitation of H3K18ac-containing nucleosomes or chromatin fragments?

Successful immunoprecipitation of H3K18ac requires careful attention to several factors:

• Sample preparation:

  • Minimize deacetylase activity by including HDAC inhibitors (e.g., sodium butyrate, TSA) in buffers

  • Use fresh samples whenever possible

  • Maintain cold temperatures throughout extraction and IP procedures

• Chromatin preparation for ChIP:

  • Optimize crosslinking conditions (1% formaldehyde, 10 minutes at room temperature)

  • Ensure proper chromatin fragmentation (200-500 bp)

  • Pre-clear chromatin with protein A/G beads to reduce non-specific binding

• Antibody selection and handling:

  • For ChIP-seq: Cell Signaling's D8Z5H antibody (#13998) at 10 μl per 10 μg chromatin is recommended

  • For conventional ChIP: 1:25 to 1:50 dilution or 5 μg of antibody per experiment

  • Pre-incubate antibody with chromatin before adding beads for better antigen recognition

• Wash conditions:

  • Use progressively stringent wash buffers

  • Perform sufficient washing steps (at least 3-5 washes)

  • Maintain consistent washing times between experiments

• Elution and downstream analysis:

  • For ChIP-qPCR: Design primers for known H3K18ac-enriched regions as positive controls

  • For ChIP-seq: Include input normalization and use appropriate peak calling algorithms

  • For proteomics: Consider on-bead digestion to minimize protein loss

A detailed protocol example from published literature demonstrates that ChIP performed on HeLa cells with H3K18ac antibody (RM166, 5 μg) followed by real-time PCR with gene-specific primers can successfully detect differential enrichment between sodium butyrate-treated and untreated cells .

How are new technologies advancing the study of H3K18 acetylation in single cells and in vivo contexts?

Cutting-edge technologies are revolutionizing H3K18ac research:

• Single-cell epigenomics:

  • Single-cell ChIP-seq adaptations for H3K18ac profiling

  • CUT&RUN and CUT&Tag methodologies requiring fewer cells

  • Integration with single-cell transcriptomics for multi-omic analyses

• In vivo imaging approaches:

  • Development of acetylation-specific intrabodies

  • FRET-based histone modification sensors

  • Live animal imaging of histone modification dynamics

• Targeted epigenome editing:

  • CRISPR-based targeted acetylation/deacetylation (dCas9-p300/HDAC fusions)

  • Optogenetic control of histone acetyltransferase activity

  • Chemical-inducible systems for temporal control of acetylation

• High-resolution structural studies:

  • Cryo-EM visualization of H3K18ac-modified nucleosomes

  • Single-molecule FRET to study conformational changes

  • Hydrogen-deuterium exchange mass spectrometry to analyze structural dynamics

These technologies are enabling unprecedented insights into the spatial and temporal dynamics of H3K18 acetylation in complex biological systems.

What are the implications of H3K18 acetylation patterns in disease biomarker development and therapeutic targeting?

H3K18 acetylation has significant implications for disease understanding and treatment:

• Cancer biomarkers:

  • Altered H3K18ac patterns correlate with tumor formation

  • Low levels of H3K18ac associate with poorer prognosis in certain cancers

  • Potential for development of diagnostic and prognostic assays based on H3K18ac detection

• Therapeutic targeting:

  • HDAC inhibitors increase H3K18 acetylation and may reverse aberrant patterns

  • Specific HAT (CBP/p300) inhibitors for contexts where H3K18 hyperacetylation drives disease

  • Development of reader domain inhibitors to block recognition of H3K18ac

• Personalized medicine applications:

  • H3K18ac profiles may predict response to epigenetic therapies

  • Combination therapies targeting both acetylation writers and readers

  • Patient stratification based on H3K18ac patterns

• Beyond cancer:

  • Emerging roles in neurodegenerative diseases

  • Implications in inflammatory conditions

  • Potential involvement in metabolic disorders

The quantitative detection of acetyl histone H3-K18 provides valuable information for understanding epigenetic regulation of gene activation and for developing HAT or HDAC-targeted drugs .

What methodological advances are needed to better understand the kinetics and spatial organization of H3K18 acetylation?

Several methodological advancements would significantly advance H3K18ac research:

• Temporal resolution improvements:

  • Development of faster ChIP protocols (minutes instead of days)

  • Real-time acetylation sensors with improved sensitivity

  • Pulse-chase approaches with bioorthogonal chemistry to track acetylation dynamics

• Spatial organization analysis:

  • Super-resolution microscopy techniques optimized for specific histone modifications

  • Chromosome conformation capture methods (Hi-C) integrated with H3K18ac ChIP

  • Genome architecture mapping with H3K18ac correlation

• Quantitative modeling:

  • Mathematical models of acetylation/deacetylation kinetics

  • Computational frameworks to predict acetylation patterns from genomic features

  • Integration of multi-omic data into predictive models of H3K18ac function

• Technological needs:

  • More specific antibodies with reduced lot-to-lot variability

  • Simplified ChIP protocols with higher reproducibility

  • Non-antibody-based detection methods for acetylation

  • Improved mass spectrometry approaches for acetylation site mapping